Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

Back in 2020, the company announced it would give up the development of VX-814, a potential treatment for alpha-1 antitrypsin ...

The company is well supported by lengthy patent protections extending as far as 2037 and first-mover status in the lucrative cystic fibrosis market. Additionally, Vertex holds significant patient ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...